Nucleic acid compositions for stimulating immune responses
View Patent ↗The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
1. A composition comprising
an immunostimulatory nucleic acid comprising the nucleotide sequence of SEQ ID NO:1.
2. The composition of claim 1 , wherein the immunostimulatory nucleic acid consists of the nucleotide sequence of SEQ ID NO:1.
3. The composition of claim 1 , further comprising an antigen.
4. The composition of claim 3 , wherein the antigen is selected from the group consisting of a microbial antigen, a cancer antigen, and an allergen.
5. The composition of claim 4 , wherein the microbial antigen is selected from the group consisting of a bacterial antigen, a viral antigen, a fungal antigen and a parasitic antigen.
6. The composition of claim 3 , wherein the antigen is encoded by a nucleic acid vector.
7. The composition of claim 3 , wherein the nucleic acid vector is separate from the immunostimulatory nucleic acid.
8. The composition of claim 3 , wherein the antigen is a peptide antigen.
9. The composition of claim 1 , further comprising an adjuvant.
10. The composition of claim 9 , wherein the adjuvant is a mucosal adjuvant.
11. The composition of claim 1 , further comprising a cytokine.
12. The composition of claim 1 , further comprising a therapeutic agent selected from the group consisting of an anti-microbial agent, an anti-cancer agent, and an allergy/asthma medicament.
13. The composition of claim 12 , wherein the anti-microbial agent is selected from the group consisting of an anti-bacterial agent, an anti-viral agent, an anti-fungal agent, and an anti-parasite agent.
14. The composition of claim 12 , wherein the allergy/asthma medicament is selected from the group consisting of PDE-4 inhibitor, bronchodilator/beta-2 agonist, K+ channel opener, VLA-4 antagonist, neurokin antagonist, TXA2 synthesis inhibitor, xanthanine, arachidonic acid antagonist, 5 lipoxygenase inhibitor, thromboxin A2 receptor antagonist, thromboxane A2 antagonist, inhibitor of 5-lipox activation protein, and protease inhibitor.
15. The composition of claim 1 , wherein the immunostimulatory nucleic acid has a nucleotide backbone which includes at least one phosphorothioate backbone modification.
16. The composition of claim 15 , wherein the nucleotide backbone is entirely modified.
17. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
18. The composition of claim 1 , wherein the immunostimulatory nucleic acid includes more than four CpG motifs.
19. The composition of claim 1 , wherein the immunostimulatory nucleic acid is formulated as a nutritional supplement.
20. The composition of claim 19 , wherein the nutritional supplement is formulated as a capsule, a pill, or a sublingual tablet.
21. The composition of claim 1 , wherein the immunostimulatory nucleic acid is formulated for local administration.
22. The composition of claim 1 , wherein the immunostimulatory nucleic acid is formulated for parenteral administration.
23. The composition of claim 1 , wherein the immunostimulatory nucleic acid is formulated in a sustained release device.
24. The composition of claim 1 , wherein the immunostimulatory nucleic acid is formulated for delivery to a mucosal surface.
25. The composition of claim 23 , wherein the sustained release device is a microparticle.
26. A method for stimulating an immune response in a subject in need thereof comprising
administering to a subject an immunostimulatory nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, in an amount effective to stimulate an immune response.
27. A method for inducing an innate immune response, comprising administering to the subject an immunostimulatory nucleic acid in an amount effective for activating an innate immune response, wherein the immunostimulatory nucleic acid has a nucleotide sequence comprising SEQ ID NO:1.
28. The composition of claim 1 , wherein the immunostimulatory nucleic acid is up to 100 nucleotides in length.
29. The method of claim 26 or 27 , wherein the immunostimulatory nucleic acid is up to 100 nucleotides in length.